Brii Biosciences

Explore the latest insights on Brii Biosciences and its impact on China’s pharmaceutical industry. Fineline Info & Tech delivers reliable data, news, and intelligence to help you navigate the complexities of Brii Biosciences’s developments with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

Explore the latest insights on Brii Biosciences and its impact on China's pharmaceutical industry. Fineline Info & Tech delivers reliable data, news, and intelligence to help you navigate the complexities of Brii Biosciences's developments with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

Alcon Acquires Neurotech Pharmaceuticals for USD 550 Million – Deal Brings ENCELTO, First FDA‑Approved MacTel Type 2 Therapy, Into Retina Portfolio
CompanyDeals

Alcon Acquires Neurotech Pharmaceuticals for USD 550 Million – Deal Brings ENCELTO, First FDA‑Approved MacTel Type 2 Therapy, Into Retina Portfolio

Alcon Laboratories, Inc. (NYSE: ALC), the US‑based eye care company, announced that it has acquired Neurotech Pharmaceuticals, Inc., a developer of innovative cell therapies for chronic and neurodegenerative eye diseases,…

Cutia Therapeutics Expands CU-20401 Licensing Collaboration with Rejuven Dermaceutical Beyond Asia – Recombinant Mutant Collagenase for Localized Fat Reduction Goes Global

Cutia Therapeutics Expands CU-20401 Licensing Collaboration with Rejuven Dermaceutical Beyond Asia – Recombinant Mutant Collagenase for Localized Fat Reduction Goes Global

Sihuan Pharmaceutical's PCL Facial Filler and L‑Carnosine Skin Booster Win Hong Kong Market Approval – Meiyan Space Aesthetics Duo Expands Beyond Mainland China

Sihuan Pharmaceutical’s PCL Facial Filler and L‑Carnosine Skin Booster Win Hong Kong Market Approval – Meiyan Space Aesthetics Duo Expands Beyond Mainland China

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
CompanyDrug

Brii Biosciences Partners Present Chronic Hepatitis B Clinical Results at EASL 2023

CompanyDeals

Shionogi’s Acquisition of Qpex Impacts Brii Biosciences’ Rights to Anti-infective Drugs

CompanyDrug

Brii Biosciences Initiates Phase I Study for BRII-297 in Australia

CompanyDrug

Brii Biosciences Halts Development of Antibody Cocktail for COVID-19 Treatment

CompanyDeals

Brii Biosciences Publishes Positive Phase II Results for HBV Treatment

CompanyDrug

Brii Biosciences Reports Positive Phase I Results for HIV Treatments BRII-732 and BRII-778

CompanyDrug

Brii Biosciences Publishes Positive Phase I Results for PPD Therapy BRII-296

Company

Everest Medicines Appoints Rogers Yongqing Luo as New CEO

Show More